Credibility and trustworthiness in AI models are related but distinct attributes. If you're using them in GMP manufacturing, you should understand the difference.
- A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
- Affinity Membranes Are Moving Closer To Commercial Reality
- AI Has Arrived In Biotech CMC Amid Patchwork Governance
- Avoiding Common Pitfalls In CDMO–Sponsor Relationships Through Integrated Execution Models
- The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process
- CDMO Selection: Start With The Relationship, Not The RFP
- Why FAT Should Confirm Alignment, Not Reveal Its Absence
GUEST COLUMNISTS
-
A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
This is the first published application of data envelopment analysis to six major pharmaceutical analytical validation guidelines, including ICH Q2(R2), USP, ChP, and Brazil's ANVISA.
-
Affinity Membranes Are Moving Closer To Commercial Reality
A recent review shows advances in surface chemistry and ligand engineering are moving the needle for next-generation affinity membranes.
-
AI Has Arrived In Biotech CMC Amid Patchwork Governance
AI is surfacing within regulatory and CMC workflows at a vigorous pace. Unfortunately, in small and midsize biotechs, it's happening faster than governance can keep up.
-
Avoiding Common Pitfalls In CDMO–Sponsor Relationships Through Integrated Execution Models
Let's delve into the key pitfalls to avoid when working with a CDMO and the integrated execution model that solves or mitigates these pitfalls before they occur.
-
The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process
Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.
-
CDMO Selection: Start With The Relationship, Not The RFP
Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.
-
Why FAT Should Confirm Alignment, Not Reveal Its Absence
In many aseptic fill/finish projects, the factory acceptance test (FAT) has become the first true integration test of the entire project. That is a problem. Here's how to flip that mindset.
BIOSIMILAR WHITE PAPERS
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
Is Sustainability The Key To Agile Biopharma Manufacturing?3/18/2025
In biologics manufacturing, change is constant. Discover how new innovations and a focus on sustainability have gotten 62% of executives to prioritize eco-friendly practices, which reflects a commitment to long-term viability.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing5/12/2025
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
Perfusion Cell Line Development For Intensified Processes5/5/2025
The biopharmaceutical industry is transforming by shifting to continuous and intensified upstream bioprocesses, which are driven by evolving demands. Discover the key goals and innovations shaping this transition for modern healthcare.
-
2024 Global Biopharma Sustainability Review9/3/2024
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?
-
A Risk-Based Approach To Plasmid DNA And mRNA Process Development9/23/2025
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Alvotech Announces FDA Acceptance Of Biologics License Application For AVT16, A Proposed Interchangeable Biosimilar To Entyvio®
- Xbrane Biopharma AB And JOINN Biologics US Inc. Enter Strategic Partnership To Develop Xdarzane – Xbrane´s Biosimilar Candidate To Darzalex (Daratumumab)
- Organon Secures US Food And Drug Administration Approval Expanding Indications For TOFIDENCE (tocilizumab-bavi) In Cytokine Release Syndrome (CRS) And Pediatric COVID-19
- GlycoNex Announces Positive Topline Results For Phase III Clinical Trial Of Denosumab Biosimilar SPD8
- Bio Techne And Refeyn Close Critical Gap In Bispecific Antibody And Biosimilar Characterization
- Alvotech Announces Resubmission Of U.S. Biologics License Applications For AVT05, A Proposed Biosimilar To Simponi® And Simponi Aria®, And AVT06, A Proposed Biosimilar To Eylea®
- AEON Biopharma To Present Data Demonstrating Structural And Functional Comparability Of ABP-450 To BOTOX® At The 68th Annual Scientific Meeting Of The American Headache Society
- Kashiv BioSciences Announces Validation And Acceptance Of Market Authorization Application By Health Canada For ADL-018, A Proposed Biosimilar To XOLAIR (omalizumab)
NEWSLETTER ARCHIVE
- 06.18.26 -- Will FDA's One-Day Inspection Pilot Stand The Test Of Time?
- 06.11.26 -- Process Intensification: Your Guide To "Doing More With Less"
- 06.04.26 -- Are Biotechs Wasting Time On The Wrong CDMO?
- 05.21.26 -- Minimizing Regulatory Risk For Biologics Manufacturing Changes
- 05.14.26 -- Do Changes Signal The End Of Biosimilar Regulatory Redundancy?